Paper
0
Adjuvant Docetaxel for Node-Positive Breast Cancer
Authors
Miguel Martín,Tadeusz Pieńkowski
John Mackey,Marek Pawlicki,Jean‐Paul Guastalla,CH Weaver,Eva Tomiak,Taher Al‐Tweigeri,Linnea Chap,É Juhos,R. Guévin,Anthony Howell,Tommy� Fornander,John Hainsworth,Robert Coleman,J. Vinholes,Manuel Modiano,Tamás Pintér,Shou-Ching Tang,Bruce Colwell,Catherine Prady,Louise Provencher,David Walde,Álvaro Rodríguez-Lescure,Judith Hugh,Camille Loret,Matthieu Rupin,Sandra Blitz,Philip Jacobs,M Murawsky,A. Riva
+29 authors
,Charles VogelPublished
Jun 1, 2005
Show more
Save
Tip0
TipSave
Abstract
We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.